Crystal structure of the peroxisome proliferator-activated receptor gamma (PPARgamma) ligand binding domain complexed with a novel partial agonist: a new region of the hydrophobic pocket could be exploited for drug design
about
Review of the Structural and Dynamic Mechanisms of PPARγ Partial AgonismThe nuclear receptor PPARγ individually responds to serotonin- and fatty acid-metabolitesResveratrol and Its Metabolites Bind to PPARsStructural basis of the transactivation deficiency of the human PPARγ F360L mutant associated with familial partial lipodystrophyA compound-based proteomic approach discloses 15-ketoatractyligenin methyl ester as a new PPARγ partial agonist with anti-proliferative abilityVirtual Screening as a Technique for PPAR Modulator Discovery.Betulinic acid is a PPARγ antagonist that improves glucose uptake, promotes osteogenesis and inhibits adipogenesis.Pharmacophore modeling improves virtual screening for novel peroxisome proliferator-activated receptor-gamma ligands.Benzbromarone, an old uricosuric drug, inhibits human fatty acid binding protein 4 in vitro and lowers the blood glucose level in db/db mice.Structural review of PPARγ in complex with ligands: Cartesian- and dihedral angle principal component analyses of X-ray crystallographic data.SR2067 Reveals a Unique Kinetic and Structural Signature for PPARγ Partial Agonism.LT175 is a novel PPARα/γ ligand with potent insulin-sensitizing effects and reduced adipogenic properties.Designing drugs with multi-target activity: the next step in the treatment of neurodegenerative disorders.Peroxisome proliferator-activated receptor α ligands and modulators from dietary compounds: Types, screening methods and functions.Structural basis for PPAR partial or full activation revealed by a novel ligand binding mode.Screening of saponins and sapogenins from Medicago species as potential PPARγ agonists and X-ray structure of the complex PPARγ/caulophyllogenin.Dihydrosanguinarine Enhances Glucose Uptake in Mouse 3T3-L1 Cells.Cefminox, a Dual Agonist of Prostacyclin Receptor and Peroxisome Proliferator-Activated Receptor-Gamma Identified by Virtual Screening, Has Therapeutic Efficacy against Hypoxia-Induced Pulmonary Hypertension in Rats.A structural mechanism for directing corepressor-selective inverse agonism of PPARγSAR and Computer-Aided Drug Design Approaches in the Discovery of Peroxisome Proliferator-Activated ReceptorγActivators: A Perspective
P2860
Q26782232-89A1E76D-2EB8-4E7B-8A4F-D386B1D969B4Q27664075-949F3C87-FA8D-4624-970B-78466C0263CAQ27683643-DE80026A-CC2A-4BED-AF5A-20F477BE3756Q27694510-D249C5AF-AA6A-4AFA-84D9-5C624DF3FC58Q28818450-AC5A81AA-7B72-4685-B687-B31BCBB4B098Q33502225-2D7602F3-667A-41C5-AF31-1E8D1C1B5298Q33916179-1A489D39-5D83-4A28-B914-3E5E31584220Q35395528-00B6A969-2D23-4C96-A69B-62541CD32FF8Q36294824-17D46242-4DBD-4566-86C3-B8B4E53FCACAQ36381221-C2D927C7-BE0D-4FA2-9226-2C27A07B77FBQ36760160-6BE56CA8-4240-4C4C-AEE7-CBD3504E6DE8Q37622614-4E75E59A-8316-4DAC-8680-28B60455F9F3Q38066606-06F39677-4884-4E6B-B68E-4F5BC9F84130Q39013200-BADD9AE1-71C3-4D90-8C0D-AF3039F8CCBDQ41343506-7D0F5633-3DC6-497B-8BC7-A4F9A670D11CQ41826885-3F06EE6E-8AD0-4CD2-8AE4-66C1470FDA5AQ47095014-997E250F-FAD1-4635-8125-8EB081AB719FQ50416961-8EFDB214-3A48-4119-A9B8-2C97B56C56ECQ58586525-340676E1-B635-4FF4-81AD-BAB328AFD79EQ58919671-287F00DF-19CA-47DC-9D7D-D0C8BB907B12
P2860
Crystal structure of the peroxisome proliferator-activated receptor gamma (PPARgamma) ligand binding domain complexed with a novel partial agonist: a new region of the hydrophobic pocket could be exploited for drug design
description
2008 nî lūn-bûn
@nan
2008 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Crystal structure of the perox ...... d be exploited for drug design
@ast
Crystal structure of the perox ...... d be exploited for drug design
@en
Crystal structure of the perox ...... d be exploited for drug design
@nl
type
label
Crystal structure of the perox ...... d be exploited for drug design
@ast
Crystal structure of the perox ...... d be exploited for drug design
@en
Crystal structure of the perox ...... d be exploited for drug design
@nl
prefLabel
Crystal structure of the perox ...... d be exploited for drug design
@ast
Crystal structure of the perox ...... d be exploited for drug design
@en
Crystal structure of the perox ...... d be exploited for drug design
@nl
P2093
P50
P921
P3181
P356
P1476
Crystal structure of the perox ...... d be exploited for drug design
@en
P2093
Cristina Godio
Elena Scotti
Fernando Mazza
Fulvio Loiodice
Fulvio Saccoccia
Giorgio Pochetti
Paolo Tortorella
Roberta Montanari
P304
P3181
P356
10.1021/JM800733H
P407
P50
P577
2008-12-25T00:00:00Z